[Clinical evaluation of pipothiazine and its palmitic ester in the therapy of schizophrenia].
20 schizophrenic patients presenting with an acute episode were treated first, whilst hospitalized, by a single oral dose of pipotiazine, then, when their symptomatology had been controlled, thus allowing their discharge, by a monthly injection of pipotiazine palmitate for 6 months. The patients were assessed with a CGI and the BPRS. The tablets provided control of the symptoms of most patients as early as the second week of treatment, the improvement bearing particularly on thought disorder, concept disorganization, excitation, anxiety, depression, tension and somatic symptoms. This led to an improvement in activities and sociability. Injections not only provided the prevention of relapses but even an improvement over the already obtained results which allowed these patients to insert themselves in the community. Adverse effects were infrequent and easily controlled. There were no abnormal modifications of the vital signs and laboratory tests. Pipotiazine appears as an extremely useful drug for countries in which the psychiatric treatment network is still being constructed.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D010640:Phenothiazines
Evaluation clinique de la pipotiazine et de son ester palmitique dans le traitement de la schizophrénie.